The United States Food and Drug Administration has permitted the marketing of the first ever medical device that uses artificial intelligence to detect mild levels of diabetic retinopathy, an eye disease found in adults who suffer from diabetes. The device can be used by a primary care doctor, as opposed to an eye specialist, to determine whether the patient has “more than mild” or “negative for more than mild” diabetic retinopathy. If the device determines that they have more than mild symptoms, the patient is then recommended to a specialist for further evaluation and to begin treatment.
